


# AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the Application.

## LISTING OF CLAIMS:

- 1-8. (cancelled)
9. (currently amended) The A compound according to ~~claim 8~~, of Formula IV.



IV

or a pharmaceutically acceptable salt thereof, wherein

X is selected from -H, -OR<sup>6</sup>, -S(O)<sub>0-2</sub>R<sup>6</sup>, -N(R<sup>6</sup>)R<sup>7</sup>, -O-N(R<sup>6</sup>)R<sup>7</sup>, -N(R<sup>6</sup>)OR<sup>6</sup>,

-N(R<sup>6</sup>)N(R<sup>6</sup>)R<sup>7</sup>, absent, oxo, thiono, and imino, with the proviso that when X is oxo, thiono, or imino, there is only one R<sup>1</sup>;

R<sup>1</sup> and R<sup>2</sup>, at each occurrence, are each independently selected from -H, halogen, -CN, -NH<sub>2</sub>, -NO<sub>2</sub>, -OR<sup>6</sup>, -N(R<sup>6</sup>)R<sup>7</sup>, -S(O)<sub>0-2</sub>R<sup>7</sup>, -SO<sub>2</sub>N(R<sup>6</sup>)R<sup>7</sup>, -CO<sub>2</sub>R<sup>6</sup>, -C(O)N(R<sup>6</sup>)R<sup>7</sup>, -N(R<sup>6</sup>)SO<sub>2</sub>R<sup>7</sup>, -N(R<sup>6</sup>)C(O)R<sup>7</sup>, -N(R<sup>6</sup>)CO<sub>2</sub>R<sup>7</sup>, -C(O)R<sup>6</sup>, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, absent, and optionally substituted lower heterocyclalkyl;

~~optionally two of R<sup>2</sup> together are exo;~~

**optionally**, at least one pair of substituents, selected from two of R<sup>1</sup>, ~~two~~ one of R<sup>2</sup>, and one each of R<sup>1</sup> and R<sup>2</sup>, together with the corresponding carbon or carbons to which they are attached, form a first ring comprising between three and seven annular atoms, said first ring optionally substituted with between zero and four additional of R<sup>1</sup>, each

independently selected as defined above and optionally, when paired, together with the corresponding atom or atoms of the first ring to which they are attached, form a second ring comprising between three and seven annular atoms, said second ring optionally substituted with between zero and three of  $R^1$ ;

$R^3$  is selected from -H and optionally substituted lower alkyl;

~~$R^2$  is selected from -H, optionally substituted lower alkyl, optionally substituted lower arylalkyl, optionally substituted aryl, optionally substituted heterocyclyl, and optionally substituted alkoxy;~~

~~optionally  $R^3$  and one of  $R^2$ , together with the atoms to which each is attached, form a third ring comprising between three and seven annular atoms, said third ring optionally substituted with between zero and four additional of  $R^1$ , each independently selected as defined above and optionally, when paired, together with the corresponding atom or atoms of the third ring to which they are attached, form a fourth ring comprising between three and seven annular atoms, said fourth ring optionally substituted with between zero and three of  $R^1$ ;~~

~~optionally  $R^3$  and one of  $R^1$ , together with the atoms to which they are attached and the carbon to which  $R^2$  is attached, form a fifth ring comprising between three and seven annular atoms, said fifth ring optionally substituted with between zero and four additional of  $R^1$ , each independently selected as defined above and optionally, when paired, together with the corresponding atom or atoms of the fifth ring to which they are attached, form a sixth ring comprising between three and seven annular atoms, said sixth ring optionally substituted with between zero and three of  $R^1$ ;~~

$m$  is zero to four;

each of  $R^4$  is independently selected from -H, halogen, -CN, -NH<sub>2</sub>, -NO<sub>2</sub>, -OR<sup>6</sup>, -N(R<sup>6</sup>)R<sup>7</sup>, -S(O)<sub>0-2</sub>R<sup>7</sup>, -SO<sub>2</sub>N(R<sup>6</sup>)R<sup>7</sup>, -CO<sub>2</sub>R<sup>6</sup>, -C(O)N(R<sup>6</sup>)R<sup>7</sup>, -N(R<sup>6</sup>)SO<sub>2</sub>R<sup>7</sup>, -N(R<sup>6</sup>)C(O)R<sup>7</sup>, -N(R<sup>6</sup>)CO<sub>2</sub>R<sup>7</sup>, -C(O)R<sup>6</sup>, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl;

n is zero to four five;

each  $R^5$  is independently selected from -H, halogen, -CN, -NH<sub>2</sub>, -NO<sub>2</sub>, -OR<sup>6</sup>, -NR<sup>6</sup>R<sup>7</sup>, -S(O)<sub>0-2</sub>R<sup>7</sup>, -SO<sub>2</sub>NR<sup>6</sup>R<sup>7</sup>, -CO<sub>2</sub>R<sup>6</sup>, -C(O)NR<sup>6</sup>R<sup>7</sup>, -N(R<sup>6</sup>)SO<sub>2</sub>R<sup>7</sup>, -N(R<sup>6</sup>)C(O)R<sup>7</sup>, -N(R<sup>6</sup>)CO<sub>2</sub>R<sup>7</sup>, -C(O)R<sup>6</sup>, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl; and

R<sup>6</sup> is -H or optionally substituted lower alkyl R<sup>2</sup>;

R<sup>7</sup> is selected from optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl; and


R<sup>6</sup> and R<sup>7</sup>, when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl ring, said optionally substituted five- to seven-membered heterocyclyl ring optionally containing at least one additional heteroatom selected from N, O, S, and P.

10. (withdrawn) The compound according to claim 9, wherein X is selected from -OR<sup>6</sup>, -SR<sup>6</sup>, and -N(R<sup>6</sup>)R<sup>7</sup>.

11. (withdrawn) The compound according to claim 10, wherein two of R<sup>1</sup>, together with the carbon or carbons to which they are attached, form said second ring.


12. (withdrawn) The compound according to claim 11, wherein said second ring is a six-membered aryl, fused with said first ring, said second ring optionally substituted with between zero and three of R<sup>1</sup>.

13. (withdrawn) The compound according to claim 12, of formula V.



V

14. (withdrawn) The compound according to claim 13, wherein X is -OR<sup>6</sup>.
15. (withdrawn) The compound according to claim 14, wherein R<sup>3</sup> is -H.
16. (withdrawn) The compound according to claim 15, wherein X is -OH.
17. (withdrawn) The compound according to claim 16, of formula VI.



VI

18. (withdrawn) The compound according to claim 17, wherein R<sup>1</sup>, R<sup>4</sup>, and R<sup>5</sup> are -H.
- 19-29. (cancelled)
30. (previously presented) A compound according to Table 3:






Table 3

#	Name	Structure
1	N-cyclohexyl-2-pyridin-4-ylquinazolin-4-amine	
3	N-cyclopentyl-2-pyridin-4-ylquinazolin-4-amine	





Table 3

#	Name	Structure
4	N-(cyclohexylmethyl)-2-pyridin-4-ylquinazolin-4-amine	
7	N-[(4-fluorophenyl)methyl]-2-pyridin-4-ylquinazolin-4-amine	
9	N-(2,3-dihydro-1H-inden-1-yl)-2-pyridin-4-ylquinazolin-4-amine	
12	2-pyridin-4-yl-N-[(2R)-1,2,3,4-tetrahydronaphthalen-2-yl]quinazolin-4-amine	
15	2-pyridin-4-yl-N-[(2S)-1,2,3,4-tetrahydronaphthalen-2-yl]quinazolin-4-amine	






**Table 3**

#	Name	Structure
18	(1S,2R)-1-[(2-pyridin-4-ylquinazolin-4-yl)amino]-2,3-dihydro-1H-inden-2-ol	
19	1,1-dimethylethyl 4-[(2-pyridin-4-ylquinazolin-4-yl)amino]piperidine-1-carboxylate	
24	3-[(2-pyridin-4-ylquinazolin-4-yl)amino]naphthalen-2-ol	
25	N-{4-[(1-methylethyl)oxy]phenyl}-2-pyridin-4-ylquinazolin-4-amine	
31	(1S,2R)-1-[(6-chloro-2-pyridin-4-ylquinazolin-4-yl)amino]-2,3-dihydro-1H-inden-2-ol	

**Table 3**






#	Name	Structure
33	(1S,2R)-1-[(2-pyridin-3-ylquinazolin-4-yl)amino]-2,3-dihydro-1H-inden-2-ol	
45	(1S,2R)-1-[(6-bromo-2-pyridin-4-ylquinazolin-4-yl)amino]-2,3-dihydro-1H-inden-2-ol	
46	(1S,2R)-1-[[6,7-bis(methoxy)-2-pyridin-4-ylquinazolin-4-yl]amino]-2,3-dihydro-1H-inden-2-ol	
48	(1S,2R)-1-[[2-pyridin-4-yl-7-(trifluoromethyl)quinazolin-4-yl]amino]-2,3-dihydro-1H-inden-2-ol	

**Table 3**

#	Name	Structure
49	(1S,2R)-1-({2-[6-(methoxy)pyridin-3-yl]quinazolin-4-yl} amino)-2,3-dihydro-1H-inden-2-ol	
51	(1S,2R)-1-[(7-methyl-2-pyridin-4-yl)quinazolin-4-yl]amino)-2,3-dihydro-1H-inden-2-ol	
54	(2S)-3-methyl-2-[(2-pyridin-4-yl)quinazolin-4-yl]amino]butan-1-ol	
55	(2S)-2-phenyl-2-[(2-pyridin-4-yl)quinazolin-4-yl]amino]ethanol	
56	(2R)-2-phenyl-2-[(2-pyridin-4-yl)quinazolin-4-yl]amino]ethanol	



**Table 3**

#	Name	Structure
61	(2S)-3-phenyl-2-[(2-pyridin-4-ylquinazolin-4-yl)amino]propan-1-ol	
62	2-[(phenylmethyl)(2-pyridin-4-ylquinazolin-4-yl)amino]ethanol	
63	(1S,2R)-1-{[2-(2-aminopyrimidin-4-yl)quinazolin-4-yl]amino}-2,3-dihydro-1H-inden-2-ol	
66	2-{4-[(2-pyridin-4-ylquinazolin-4-yl)amino]piperazin-1-yl}ethanol	
67	N-piperidin-1-yl-2-pyridin-4-ylquinazolin-4-amine	

31. (previously presented) A pharmaceutical composition comprising the compound according to claim 9 and a pharmaceutically acceptable carrier.

32-38. (cancelled)